X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-04-24 | ETST | Earth Science Tech, Inc. | Sanchez Yovan Arturo | Dir | P - Purchase | $0.06 | +92,530 | 742,530 | +14% | +$5,459 | |||||
| D | 2024-04-25 | MAIA | Maia Biotechnology, Inc. | Louie Ngar Yee | Dir | P - Purchase | $2.03 | +19,665 | 1,167,189 | +2% | +$39,920 | |||||
| D | 2024-04-25 | MAIA | Maia Biotechnology, Inc. | Smith Stan | Dir | P - Purchase | $2.03 | +147,492 | 1,005,060 | +17% | +$299,409 | |||||
2024-04-25 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | SVP, GC | P - Purchase | $3.24 | +8,600 | 188,718 | +5% | +$27,864 | ||||||
2024-04-25 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | P - Purchase | $3.14 | +5,608 | 233,868 | +2% | +$17,609 | ||||||
2024-04-25 | CYTK | Cytokinetics Inc | Henderson John T | Dir | S - Sale | $64.54 | -10,562 | 32,153 | -25% | -$681,671 | ||||||
2024-04-25 | HROW | Harrow, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $9.97 | +20,000 | 3,815,000 | +1% | +$199,400 | ||||||
| DM | 2024-04-23 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $237.60 | -7,200 | 130 | -98% | -$1,710,713 | |||||
2024-04-24 | GALT | Galectin Therapeutics Inc | Lewis Joel | Pres, CEO | P - Purchase | $3.39 | +1,000 | 899,012 | 0% | +$3,390 | ||||||
| M | 2024-04-22 | GALT | Galectin Therapeutics Inc | Czirr James C | 10% | S - Sale | $3.06 | -25,000 | 5,922,207 | 0% | -$76,500 | |||||
2024-04-24 | BHVN | Biohaven Ltd. | Bailey Gregory | Dir | P - Purchase | $39.18 | +25,503 | 1,600,071 | +2% | +$999,169 | ||||||
| M | 2024-04-22 | GNLX | Genelux Corp | Szalay Aladar | 10% | S - Sale | $3.51 | -44,395 | 4,069,490 | -1% | -$155,647 | |||||
2024-04-22 | KRRO | Korro Bio, Inc. | New Enterprise Associates 17, L.P. | 10% | P - Purchase | $56.00 | +17,857 | 1,090,793 | +2% | +$999,992 | ||||||
2024-04-22 | KRRO | Korro Bio, Inc. | Baskett Forest | 10% | P - Purchase | $56.00 | +17,857 | 1,090,793 | +2% | +$999,992 | ||||||
2024-04-22 | KRRO | Korro Bio, Inc. | Florence Anthony A. Jr. | 10% | P - Purchase | $56.00 | +17,857 | 1,090,793 | +2% | +$999,992 | ||||||
2024-04-22 | KRRO | Korro Bio, Inc. | Walker Paul Edward | 10% | P - Purchase | $56.00 | +17,857 | 1,090,793 | +2% | +$999,992 | ||||||
2024-04-22 | KRRO | Korro Bio, Inc. | Chang Carmen | 10% | P - Purchase | $56.00 | +17,857 | 1,090,793 | +2% | +$999,992 | ||||||
2024-04-22 | KRRO | Korro Bio, Inc. | Mathers Edward T | 10% | P - Purchase | $56.00 | +17,857 | 1,090,793 | +2% | +$999,992 | ||||||
2024-04-22 | KRRO | Korro Bio, Inc. | Yang Rick | 10% | P - Purchase | $56.00 | +17,857 | 1,090,793 | +2% | +$999,992 | ||||||
2024-04-22 | KRRO | Korro Bio, Inc. | Makhzoumi Mohamad | 10% | P - Purchase | $56.00 | +17,857 | 1,090,793 | +2% | +$999,992 | ||||||
2024-04-22 | KRRO | Korro Bio, Inc. | Sandell Scott D | 10% | P - Purchase | $56.00 | +17,857 | 1,090,793 | +2% | +$999,992 | ||||||
2024-04-22 | NUVL | Nuvalent, Inc. | Shair Matthew | Dir | S - Sale | $63.65 | -37,500 | 1,775,720 | -2% | -$2,386,910 | ||||||
| M | 2024-04-23 | HROW | Harrow, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $10.23 | +20,000 | 3,795,000 | +1% | +$204,640 | |||||
2024-04-22 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $22.87 | -833 | 54,406 | -2% | -$19,051 | ||||||
2024-04-24 | BSPK | Bespoke Extracts, Inc. | Feinsod Michael | CEO, 10% | P - Purchase | $0.11 | +5,000 | 2,130,112 | 0% | +$550 | ||||||
2024-04-19 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir, 10% | P - Purchase | $0.69 | +1,000 | 1,940,259 | 0% | +$688 | ||||||
2024-04-19 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale | $13.68 | -1,649 | 211,672 | -1% | -$22,558 | ||||||
2024-04-22 | KRRO | Korro Bio, Inc. | Atlas Venture Opportunity Fund Ii, L.P. | 10% | P - Purchase | $56.00 | +17,857 | 195,074 | +10% | +$999,992 | ||||||
2024-03-25 | QTTB | Q32 Bio Inc. | Alloway Paul | See Remarks | S - Sale | $24.21 | -268 | 2,596 | -9% | -$6,488 | ||||||
2024-03-25 | QTTB | Q32 Bio Inc. | Michaud Charles Jr | See Remarks | S - Sale | $24.20 | -75 | 927 | -7% | -$1,815 | ||||||
| DM | 2024-04-19 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $236.69 | -7,200 | 130 | -98% | -$1,704,174 | |||||
2024-04-22 | KPTI | Karyopharm Therapeutics Inc. | Rangwala Reshma | EVP, Chief Medical Officer | S - Sale | $1.17 | -6,789 | 342,931 | -2% | -$7,943 | ||||||
2024-04-22 | BHVN | Biohaven Ltd. | Bailey Gregory | Dir | P - Purchase | $41.00 | +48,780 | 1,574,568 | +3% | +$1,999,980 | ||||||
2024-04-22 | BHVN | Biohaven Ltd. | Childs John W | Dir | P - Purchase | $41.00 | +195,121 | 6,375,744 | +3% | +$7,999,961 | ||||||
2024-04-22 | BHVN | Biohaven Ltd. | Coric Vlad | CEO | P - Purchase | $41.00 | +121,951 | 3,146,085 | +4% | +$4,999,991 | ||||||
2024-04-22 | ETST | Earth Science Tech, Inc. | Saumat Giorgio R. | CEO, 10% | P - Purchase | $0.07 | +79,000 | 119,910,407 | 0% | +$5,165 | ||||||
2024-04-18 | DAWN | Day One Biopharmaceuticals, Inc. | Blackman Samuel C. | HEAD OF R, D | S - Sale | $16.02 | -10,000 | 2,174,662 | 0% | -$160,163 | ||||||
| M | 2024-04-18 | ANIP | Ani Pharmaceuticals Inc | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS | S - Sale | $65.10 | -27,232 | 856,272 | -3% | -$1,772,729 | |||||
| D | 2024-04-19 | RNA | Avidity Biosciences, Inc. | Levin Arthur A | Dir | S - Sale+OE | $22.82 | -5,000 | 268,702 | -2% | -$114,123 | |||||
2024-04-19 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $24.89 | -3,361 | 225,807 | -1% | -$83,669 | ||||||
| D | 2024-04-19 | VCNX | Vaccinex, Inc. | Friedberg Albert | Dir, 10% | P - Purchase | $4.73 | +282 | 579,595 | 0% | +$1,334 | |||||
2024-04-22 | GALT | Galectin Therapeutics Inc | Freeman Kevin D | Dir | P - Purchase | $2.98 | +2,500 | 119,032 | +2% | +$7,450 | ||||||
2024-04-20 | ETST | Earth Science Tech, Inc. | Saumat Giorgio R. | CEO, 10% | P - Purchase | $0.07 | +40,000 | 119,831,407 | 0% | +$2,798 | ||||||
2024-04-18 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | CFO | S - Sale | $25.11 | -1,234 | 37,163 | -3% | -$30,986 | ||||||
2024-04-19 | HROW | Harrow, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $10.56 | +29,400 | 3,775,000 | +1% | +$310,391 | ||||||
| D | 2024-04-17 | AVTE | Aerovate Therapeutics, Inc. | Dake Benjamin T | SEE REMARKS | S - Sale+OE | $22.37 | -6,853 | 1,291 | -84% | -$153,327 | |||||
| D | 2024-04-17 | AVTE | Aerovate Therapeutics, Inc. | Gillies Hunter | CHIEF MEDICAL OFFICER | S - Sale+OE | $22.38 | -4,000 | 3,251 | -55% | -$89,522 | |||||
2024-04-17 | PTCT | Ptc Therapeutics, Inc. | Pauwels Eric | CEO | S - Sale | $25.14 | -787 | 67,694 | -1% | -$19,781 | ||||||
2024-04-17 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $25.14 | -1,307 | 229,168 | -1% | -$32,851 | ||||||
2024-04-18 | RARE | Ultragenyx Pharmaceutical Inc. | Crombez Eric | EVP, Chief Medical Officer | S - Sale | $44.10 | -142 | 48,785 | 0% | -$6,262 | ||||||
| DM | 2024-04-17 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $236.80 | -7,200 | 130 | -98% | -$1,704,990 | |||||
| D | 2024-04-18 | ME | 23Andme Holding Co. | Hibbs Kathy L | Chief Administrative Officer | S - Sale+OE | $0.47 | -38,548 | 1,252,315 | -3% | -$18,148 | |||||
| M | 2024-04-17 | CLSD | Clearside Biomedical, Inc. | Gibney Anthony S | Dir | P - Purchase | $1.30 | +100,000 | 100,000 | New | +$129,665 | |||||
| M | 2024-04-17 | ETST | Earth Science Tech, Inc. | Saumat Giorgio R. | CEO, 10% | P - Purchase | $0.07 | +89,000 | 119,791,407 | 0% | +$5,959 | |||||
| D | 2024-04-16 | AVTE | Aerovate Therapeutics, Inc. | Noyes Timothy P | CEO | S - Sale+OE | $24.70 | -10,000 | 0 | -100% | -$246,971 | |||||
| M | 2024-04-16 | GNLX | Genelux Corp | Szalay Aladar | 10% | S - Sale | $3.59 | -71,420 | 4,113,885 | -2% | -$256,227 | |||||
| D | 2024-04-16 | ALXO | Alx Oncology Holdings Inc | Pons Jaume | Pres, CSO | S - Sale+OE | $14.20 | -50,000 | 604,205 | -8% | -$710,195 | |||||
2024-04-18 | ZTS | Zoetis Inc. | Lagano Roxanne | EVP | S - Sale | $151.17 | -923 | 15,602 | -6% | -$139,530 | ||||||
2024-04-17 | STOK | Stoke Therapeutics, Inc. | Skorpios Trust | 10% | S - Sale | $11.60 | -3,600,000 | 10,843,681 | -25% | -$41,760,000 | ||||||
| M | 2024-04-16 | CMPS | Compass Pathways Plc | Goldsmith George Jay | 10% | S - Sale | $8.61 | -69,461 | 7,949,073 | -1% | -$597,964 | |||||
| M | 2024-04-16 | CMPS | Compass Pathways Plc | Malievskaia Ekaterina | 10% | S - Sale | $8.61 | -69,461 | 7,949,073 | -1% | -$597,964 | |||||
2024-04-11 | BCEL | Atreca, Inc. | Orwin John A | Pres, CEO | P - Purchase | $0.01 | +1 | 77,542 | 0% | +$0 | ||||||
2024-04-16 | SPRY | Ars Pharmaceuticals, Inc. | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.28 | -100,000 | 12,546,116 | -1% | -$928,005 | ||||||
2024-04-16 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.28 | -100,000 | 12,546,116 | -1% | -$928,005 | ||||||
| D | 2024-04-16 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale+OE | $41.60 | -4,006 | 21,271 | -16% | -$166,641 | |||||
| D | 2024-04-16 | IONS | Ionis Pharmaceuticals Inc | Birchler Brian | EVP, Corp, Development Ops | S - Sale+OE | $41.66 | -905 | 46,156 | -2% | -$37,698 | |||||
2024-04-15 | NUVL | Nuvalent, Inc. | Shair Matthew | Dir | S - Sale | $65.56 | -37,500 | 1,813,220 | -2% | -$2,458,335 | ||||||
| D | 2024-04-15 | NUVL | Nuvalent, Inc. | Conley Emily | Dir | S - Sale+OE | $65.52 | -5,000 | 8 | -100% | -$327,607 | |||||
| D | 2024-04-15 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Chief Med, Dev Officer | S - Sale+OE | $44.47 | -14,375 | 27,786 | -34% | -$639,256 | |||||
2024-04-16 | RVNC | Revance Therapeutics, Inc. | Jordan Erica | Chief Commercial Officer | S - Sale | $3.80 | -2,392 | 114,864 | -2% | -$9,096 | ||||||
| M | 2024-04-15 | ANIP | Ani Pharmaceuticals Inc | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS | S - Sale | $65.91 | -22,768 | 883,504 | -3% | -$1,500,589 | |||||
| DM | 2024-04-15 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $233.73 | -7,200 | 130 | -98% | -$1,682,819 | |||||
2024-04-15 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $7.06 | -7,500 | 1,336,297 | -1% | -$52,924 | ||||||
| A | 2024-03-12 | ALDX | Aldeyra Therapeutics, Inc. | Machatha Stephen | Chief Development Officer | S - Sale | $3.16 | -11,537 | 252,812 | -4% | -$36,503 | |||||
| A | 2024-03-11 | ALDX | Aldeyra Therapeutics, Inc. | Greenberg Bruce | See Remarks | S - Sale | $3.41 | -13,201 | 130,154 | -9% | -$44,968 | |||||
| DM | 2024-04-12 | RCKT | Rocket Pharmaceuticals, Inc. | Southwell David P | Dir | S - Sale+OE | $24.32 | -80,000 | 114,784 | -41% | -$1,945,785 | |||||
2024-04-12 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale | $14.58 | -2,060 | 500,527 | 0% | -$30,035 | ||||||
2024-04-12 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale | $14.58 | -1,525 | 213,321 | -1% | -$22,235 | ||||||
2024-04-12 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale | $14.58 | -1,585 | 151,881 | -1% | -$23,109 | ||||||
2024-04-12 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale | $14.58 | -3,136 | 315,045 | -1% | -$45,723 | ||||||
2024-04-12 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $14.58 | -8,360 | 2,415,247 | 0% | -$121,889 | ||||||
2024-04-09 | CLNN | Clene Inc. | General Resonance LLC | 10% | S - Sale | $0.39 | -22,500 | 15,428,212 | 0% | -$8,675 | ||||||
| DM | 2024-03-20 | PKTX | Protokinetix, Inc. | Smith Clarence Edward | Pres, CEO, 10% | P - Purchase | $0.01 | +3,166,667 | 77,137,093 | +4% | +$35,000 | |||||
| D | 2024-04-12 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $14.58 | -1,189 | 111,537 | -1% | -$17,336 | |||||
| D | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale+OE | $25.03 | -17,500 | 394,027 | -4% | -$438,099 | |||||
| D | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Chief Scientific Officer | S - Sale+OE | $25.04 | -30,000 | 1,117,035 | -3% | -$751,332 | |||||
| D | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Pres, CEO | S - Sale+OE | $25.04 | -47,709 | 1,264,587 | -4% | -$1,194,700 | |||||
| D | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $24.72 | -14,000 | 0 | -100% | -$346,149 | |||||
| M | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $24.11 | -6,964 | 203,129 | -3% | -$167,888 | |||||
| D | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief Medical Officer | S - Sale+OE | $25.07 | -20,000 | 0 | -100% | -$501,478 | |||||
2024-04-12 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $67.79 | -250 | 59,731 | 0% | -$16,948 | ||||||
| D | 2024-04-11 | IRON | Disc Medicine, Inc. | White William Richard | Dir | S - Sale+OE | $31.80 | -2,560 | 0 | -100% | -$81,407 | |||||
| DM | 2024-04-11 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $237.19 | -7,200 | 130 | -98% | -$1,707,775 | |||||
| DM | 2024-04-11 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | Dir | S - Sale+OE | $91.13 | -40,000 | 722,527 | -5% | -$3,645,000 | |||||
| D | 2024-04-11 | THRD | Third Harmonic Bio, Inc. | Holles Natalie C. | CEO | S - Sale+OE | $12.19 | -13,558 | 1,218,836 | -1% | -$165,214 | |||||
2024-04-11 | ACRV | Acrivon Therapeutics, Inc. | Perceptive Advisors LLC | 10% | P - Purchase | $8.50 | +2,353,000 | 5,360,858 | +78% | +$20,000,500 | ||||||
| DM | 2024-04-10 | LGVN | Longeveron Inc. | Hare Joshua | Chief Scientific Officer, 10% | P - Purchase | $2.35 | +148,936 | 633,280 | +31% | +$350,000 | |||||
| D | 2024-04-11 | LGVN | Longeveron Inc. | Hashad Mohamed Wa'El Ahmed | CEO | P - Purchase | $2.35 | +10,638 | 19,616 | +118% | +$24,999 | |||||
| DM | 2024-04-10 | LGVN | Longeveron Inc. | Soffer Rock | Dir | P - Purchase | $2.35 | +138,298 | 208,534 | +197% | +$325,000 | |||||
| DM | 2024-04-10 | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Dir | S - Sale+OE | $23.36 | -67,000 | 22,341 | -75% | -$1,564,812 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |